Today: Today, Thermo Fisher Scientific Inc. (TMO) Position Increased by Guyasuta Investment Advisors Inc.

Today, Thermo Fisher Scientific Inc. (TMO) Position Increased by Guyasuta Investment Advisors Inc.

Guyasuta Investment Advisors Inc. raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.2% during the third quarter, Holdings Channel reports. The fund owned 120,027 shares of the company’s stock after buying an additional 2,529 shares during the period. Thermo Fisher Scientific comprises about 2.4% of Guyasuta Investment Advisors Inc.’s portfolio, making the stock its 18th largest position. Guyasuta Investment Advisors Inc.’s holdings in Thermo Fisher Scientific were worth $19,091,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in TMO. Vanguard Group Inc. increased its position in shares of Thermo Fisher Scientific by 1.0% in the second quarter. Vanguard Group Inc. now owns 24,236,706 shares of the company’s stock valued at $3,581,215,000 after buying an additional 247,812 shares during the period. FMR LLC increased its position in shares of Thermo Fisher Scientific by 11.3% in the second quarter. FMR LLC now owns 8,216,645 shares of the company’s stock valued at $1,214,093,000 after buying an additional 834,858 shares during the period. BlackRock Fund Advisors increased its position in shares of Thermo Fisher Scientific by 7.5% in the second quarter. BlackRock Fund Advisors now owns 5,834,133 shares of the company’s stock valued at $862,051,000 after buying an additional 408,363 shares during the period. Carmignac Gestion increased its position in shares of Thermo Fisher Scientific by 0.5% in the third quarter. Carmignac Gestion now owns 4,065,036 shares of the company’s stock valued at $646,585,000 after buying an additional 18,486 shares during the period. Finally, Bank of New York Mellon Corp increased its position in shares of Thermo Fisher Scientific by 6.8% in the third quarter. Bank of New York Mellon Corp now owns 4,004,893 shares of the company’s stock valued at $637,017,000 after buying an additional 254,995 shares during the period. Hedge funds and other institutional investors own 86.28% of the company’s stock.

Shares of Thermo Fisher Scientific Inc. (NYSE:TMO) traded down 2.93% during trading on Monday, hitting $139.95. The stock had a trading volume of 2,382,833 shares. The company has a market capitalization of $55.28 billion, a price-to-earnings ratio of 27.97 and a beta of 1.24. The firm has a 50 day moving average of $149.80 and a 200 day moving average of $151.93. Thermo Fisher Scientific Inc. has a 1-year low of $119.75 and a 1-year high of $160.68.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, October 27th. The company reported $2.03 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.97 by $0.06. The business earned $4.49 billion during the quarter, compared to the consensus estimate of $4.39 billion. Thermo Fisher Scientific had a return on equity of 14.95% and a net margin of 11.10%. The firm’s quarterly revenue was up 8.9% on a year-over-year basis. During the same period in the previous year, the company posted $1.80 EPS. Analysts expect that Thermo Fisher Scientific Inc. will post $8.25 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Monday, January 16th. Stockholders of record on Thursday, December 15th will be given a dividend of $0.15 per share. The ex-dividend date of this dividend is Tuesday, December 13th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.42%. Thermo Fisher Scientific’s payout ratio is 12.00%.

TMO has been the subject of several analyst reports. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $178.00 price target for the company in a report on Monday, August 1st. Leerink Swann reissued a “buy” rating and set a $175.00 price target on shares of Thermo Fisher Scientific in a report on Sunday, November 20th. Cleveland Research downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “neutral” rating in a report on Friday, September 9th. Bank of America Corp. set a $180.00 price objective on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Friday, October 7th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Thermo Fisher Scientific in a report on Thursday, September 22nd. They issued an “overweight” rating and a $180.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Thermo Fisher Scientific currently has an average rating of “Buy” and an average price target of $164.37.

In other news, CEO Marc N. Casper sold 30,000 shares of the company’s stock in a transaction on Thursday, September 1st. The stock was sold at an average price of $151.17, for a total transaction of $4,535,100.00. Following the completion of the sale, the chief executive officer now directly owns 308,647 shares in the company, valued at approximately $46,658,166.99. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 28,797 shares of the company’s stock in a transaction on Friday, September 2nd. The shares were sold at an average price of $151.01, for a total value of $4,348,634.97. Following the sale, the chief executive officer now owns 307,444 shares of the company’s stock, valued at $46,427,118.44. The disclosure for this sale can be found here. Insiders own 0.52% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company is a provider of analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. The company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Related posts

Leave a Comment